secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268057
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q3 revenue $13.1M (+41% YoY); net loss narrows; IND cleared for VYD2311
-------------------------------------------------------------------------------

- PEMGARDA net product revenue $13.1M in Q3 2025, up 41% YoY and 11% QoQ.
- Net loss $10.5M ($0.06 diluted EPS) vs $60.7M ($0.51) in Q3 2024; R&D spend fell to $8.0M from $57.9M.
- Cash $85.0M at Sep 30; >$100M after Oct ATM; $57.5M gross proceeds from Aug 2025 offering.
- FDA cleared IND for VYD2311; pivotal REVOLUTION program (DECLARATION N=1770, LIBERTY N=210) starts near year-end 2025, data mid-2026.
- Board adds Dr. Paul Bolno; Kristie Kuhl named CCO; pipeline expansion into RSV and measles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/0001193125-25-268057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/d81968d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer